Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis
Schizophrenia Research · 2026-11 · 297 · 8-16
DOI: 10.1016/j.schres.2026.06.025 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Schizophrenia Research, 2026-11. Verfasst von Milene Vitória Sampaio Sobral und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Western São Paulo, Presidente Prudente, Brazil. Electronic address: milenesobral@unoeste.br. Hauptthemen laut MEDLINE: Antipsychotic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Schizophrenia, Semaglutide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Individuals with schizophrenia have markedly increased cardiometabolic morbidity, largely attributable to antipsychotic-induced weight gain, insulin resistance, and dyslipidemia, particularly with clozapine- and olanzapine-based regimens. This systematic review and meta-analysis evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in antipsychotic-treated patients with schizophrenia. METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to September 16, 2025 for randomized clinical trials comparing GLP-1RAs with placebo or standard care. The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was prospectively registered in PROSPERO (CRD420251177261). Random-effects models were used to pool mean differences (MDs) and risk ratios (RRs). RESULTS: Eight randomized clinical trials including 523 participants were analyzed. GLP-1RAs significantly reduced body weight (MD -6.47; 95% CI, -9.61 to -3.32), body mass index (MD -2.83; 95% CI, -3.81 to -1.86), waist circumference (MD -5.35; 95% CI, -6.60 to -4.09), and glycated hemoglobin levels (MD -0.32; 95% CI, -0.39 to -0.26) compared with placebo or standard care. Exploratory subgroup analyses suggested marked differences across individual agents: exenatide showed a smaller and non-significant reduction in body weight, liraglutide showed a significant moderate reduction, and semaglutide showed the largest reduction. No significant effects were observed for fasting insulin, lipid parameters, or blood pressure. Gastrointestinal adverse events were more frequent with GLP-1RAs. CONCLUSIONS: In this systematic review and meta-analysis, GLP-1RAs were associated with clinically meaningful improvements in anthropometric and glycemic outcomes in antipsychotic-treated patients with schizophrenia, with acceptable tolerability primarily characterized by gastrointestinal adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Western São Paulo, Presidente Prudente, Brazil. Electronic address: milenesobral@unoeste.br.
- University of Western São Paulo, Presidente Prudente, Brazil.
- Afya College of Medical Sciences of Santa Inês, Santa Inês, Brazil.
- Faculty of Medicine of Jundiaí, Jundiaí, Brazil.
- Santa Marcelina Medical School, Sao Paulo, Brazil.
- Federal University of Campina Grande, Campina Grande, Brazil.
Zitieren
APA
Sobral, M. V. S., Menechini, R. B., Marçal, J. B. C., de Vasconcelos, A. V., Graciolli, L. H. M. D. S. G., Maciel, R. C., Monteiro, A., Amador, W. F. O., & Acuia, T. A. S. (2026). Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 297, 8-16. https://doi.org/10.1016/j.schres.2026.06.025
Vancouver
Sobral MVS, Menechini RB, Marçal JBC, de Vasconcelos AV, Graciolli LHMDSG, Maciel RC, et al. Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis. Schizophrenia Research. 2026;297:8-16. doi:10.1016/j.schres.2026.06.025
BibTeX
@article{Sobral2026,
author = {Sobral, Milene Vitória Sampaio and Menechini, Rodrigo Bettanim and Marçal, Jordana Belgamasco Cavalcanti and de Vasconcelos, Anna Victoria and Graciolli, Letícia Hanna Moura da Silva Gattas and Maciel, Rafaela Correia and Monteiro, Amanda and Amador, Wellgner Fernandes Oliveira and Acuia, Thaísa Aparecida de Souza},
title = {Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis},
journal = {Schizophrenia Research},
year = {2026},
volume = {297},
pages = {8--16},
doi = {10.1016/j.schres.2026.06.025}
}
EUVIMED